v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Cash flows from operating activities:      
Net income $ 19,988 $ 18,241  
Adjustments to reconcile net income to net cash provided by operating activities:      
Provision for credit losses 400 $ 1,250
Depreciation and amortization of premises and equipment 724 591  
Termination of lease 1,586    
Amortization of intangibles 2,572 1,298  
Net accretion of securities (2,145) (1,374)  
Amortization of stock-based compensation 579 551  
Accretion of purchase accounting valuations (3,658) (1,017)  
Net change in deferred loan fees and costs (748) (239)  
Change in fair value of MSR and other investments (341) (693)  
Net gain on sale of OREO and valuation allowance (191)    
Proceeds from sales of mortgage loans 61,342 29,241  
Originations of mortgage loans held for sale (63,774) (28,495)  
Gain on sales of mortgage loans (1,076) (334)  
Realized loss on sale of securities 31    
Undistributed income of Ansay joint venture (975) (1,181)  
Net earnings on life insurance (743) (407)  
Increase in other assets 8,103 973  
Decrease in other liabilities (32,925) (11,389)  
Net cash (used in) provided by operating activities (11,651) 6,166  
Activity in securities available for sale and held to maturity:      
Sales 8,920    
Maturities, prepayments, and calls 17,621 256,762  
Purchases (27,189) (194,612)  
Net increase in loans 73,635 (30,417)  
Dividends received from Ansay 691 635  
Proceeds from sale of OREO 991    
Proceeds from Sale of Federal Home Loan Bank Stock 3,920    
Net purchases of Federal Reserve Bank ("FRB") stock (3,996)    
Proceeds from life insurance   1,328  
Proceeds from sale of premises and equipment 1 1  
Purchases of premises and equipment (5,241) (2,154)  
Net cash received in business combination 169,493    
Net cash provided by investing activities 238,846 31,543  
Cash flows from financing activities, net of effects of business combination:      
Net increase in deposits 14,649 13,140  
Repayment of notes payable (77,814) (508)  
Dividends paid (5,611) (4,491)  
Proceeds from sales of common stock 88 64  
Repurchase of common stock (3,076) (6,381)  
Net cash (used in) provided by financing activities (71,764) 1,824  
Net increase in cash and cash equivalents 155,431 39,533  
Cash and cash equivalents at beginning of period 243,207 261,332 261,332
Cash and cash equivalents at end of period 398,638 300,865 $ 243,207
Cash paid during the year for:      
Interest 19,316 18,724  
Income taxes 56    
Supplemental schedule of noncash activities:      
Closed branch building transferred to OREO 3,990    
MSR resulting from sale of loans 723 325  
Change in unrealized loss on investment securities available for sale, net of tax $ (4,421) $ 747